Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO) both reported Q2 2026 results in early August, and the split screen was jarring.
Lilly delivered 48% revenue growth and raised guidance. Novo defended a shrinking U.S. business with price cuts, layoffs, and a fresh round of pipeline impairments. Same week, same category, opposite momentum.
Tirzepatide Runs Hot While Wegovy Fights for Air
Lilly’s incretin engine did the heavy lifting. Mounjaro and Zepbound combined for $14.9 billion in Q2 sales, and international was where the story got loud: China grew 93% at constant currency and rest of world grew 136%. In the U.S. obesity market, roughly 6 out of 10 total prescriptions were for a Lilly medicine. That signals category dominance rather than a contested share war.
Novo’s quarter was more complicated. Adjusted sales rose 7% at constant exchange rates to 78.5 billion Danish kroner, but adjusted gross margin fell to 78.2% from 82.7% a year earlier. The one bright spot is the Wegovy pill, which CEO Mike Doustdar called “the strongest ever GLP-1 launch by volume”, reaching over 5 million total prescriptions and around 90% of the oral obesity market.
| Business Driver | Eli Lilly | Novo Nordisk |
| Q2 revenue growth | 48% | 7% CER |
| Flagship franchise | Mounjaro + Zepbound | Wegovy + Ozempic |
| U.S. price trend | Declined 3% | Lower realized prices |
| Gross margin | 85.8% range | 78.2% |
Offense in Indianapolis, Defense in Bagsvaerd
Lilly is playing offense. Retatrutide, its triple acting GLP-1, hit primary endpoints across three Phase 3 trials, with CEO Dave Ricks noting “weight loss approaching bariatric surgery levels at the highest doses” and a U.S. BLA submission slated for Q1 2027.
Orforglipron, sold as Foundayo, expanded from about 8,000 prescribers to 36,000 prescribers. Full-year revenue guidance moved to $85 to $87 billion.
Novo is playing defense. It took a DKK 6.3B non-cash impairment, retired monlunabant, and watched siltivecumab post a MACE hazard ratio of 0.99. Headcount fell by almost 12,000 employees, roughly a 15% decline.
On CNBC affiliate Mad Money, Doustdar acknowledged that “Lilly’s pill reduces your weight by 12%” versus Wegovy pill’s 17%, but conceded Lilly is “more diversified than Novo Nordisk”.
Retatrutide, Pricing, and the Bridge Program
The next 12 months hinge on three things. First, retatrutide’s regulatory path and whether Lilly’s manufacturing build in Indiana and Ireland keeps pace.
Second, whether Novo’s announced 50% list price cut for Wegovy effective January 2027 stabilizes U.S. volume.
Third, the Medicare GLP-1 Bridge Program, which Lilly says gives “20 million eligible Americans” a $50 per month option. I will keep an eye on whether that access lift accrues mostly to Zepbound and Foundayo or opens a lane for Wegovy pill.
Why I Lean Lilly, but Would Not Write Off Novo
Lilly looks like the cleaner story. Shares are up 77.98% over one year, and a 42 trailing PE is rich but arguably earned by 54.2% operating margins and retatrutide optionality.
Novo is the harder trade. At a 11 PE and a 3.84% dividend yield, the setup fits a turnaround investor who believes the Wegovy pill can carry international growth while U.S. price cuts wash through. If retatrutide gets its BLA and Novo’s amylin combos slip again, the gap widens.
If Wegovy pill scales in Germany the way it did in the UK, the underdog gets a second act. The setup argues against chasing Lilly on strength or bottom-fishing Novo on weakness without evidence the U.S. base is stabilizing.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks